Roche announces positive phase II results for dual GLP1/GIP receptor ReutersJanuary 27, 2026 at 7:12 AM 0 A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen in Burgess Hill, Britain, October 7, 2020. REUTERS/Peter Nicholls BERLIN, Jan 27 (Reuters) Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of CT388, an investigational dual GLP1/GIP receptor being developed to treat obesity, delivered positive results. (Writing by Miranda Murray)
- - Roche announces positive phase II results for dual GLP-1/GIP receptor
ReutersJanuary 27, 2026 at 7:12 AM
0
A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen in Burgess Hill, Britain, October 7, 2020. REUTERS/Peter Nicholls
BERLIN, Jan 27 (Reuters) - Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor being developed to treat obesity, delivered positive results.
(Writing by Miranda Murray)
Source: "AOL Breaking"
Source: Breaking
Published: January 27, 2026 at 01:54AM on Source: OPERA MAG
#ShowBiz#Sports#Celebrities#Lifestyle
